Rıza Taner Baran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rıza Taner Baran has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Edip Unal
Department of Pediatric Endocrinology, Faculty of Medicine Dicle University Diyarbakır Turkey
2 shared publications - Huseyin Demirbilek
Department of Paediatric Endocrine, Hacettepe University Faculty of Medicine, Ankara, Turkey
2 shared publications - Mehmet Nuri Özbek
Department of Pediatric Endocrinology, Mardin Artuklu University Faculty of Medicine, Mardin, Türkiye
2 shared publications - Meliha Demiral
Gazi Yaşargil Training and Research Hospital, Clinic of Pediatric Endocrinology, Diyarbakır, Turkey
2 shared publications - Serkan Filiz
University of Health Sciences, Antalya Education and Research Hospital
2 shared publications - Arif Önder
Department of Child and Adolescent Psychiatry, Akdeniz University School of Medicine, Antalya, Turkey
1 shared publication
Latest Publications
- 24 June 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (9) , 883-890
Iodine status and thyroid function in children with multiple food allergy: a prospective cross-sectional study
Objectives: Children with multiple food allergies (MFA) often follow elimination diets that restrict major dietary sources of iodine, thereby increasing the risk of iodine deficiency. This study aimed to evaluate urinary iodine concentration (UIC) and thyroid function parameters in children with MFA and to compare these findings with those of age- and sex-matched healthy controls. Methods: In this prospective cross-sectional study, 47 children aged 0–13 years with IgE-mediated MFA on elimination diets were compared with 52 age- and sex-matched healthy controls between October 2022 and March 2024. Serum thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4) were measured using electrochemiluminescence immunoassay, and UIC was determined by inductively coupled plasma mass spectrometry (ICP-MS). Anthropometric parameters were also assessed. Results: Serum TSH, fT3, and fT4 levels did not differ significantly between the MFA and control groups (p>0.05). However, median UIC was significantly lower in the MFA group [86 μg/L (IQR: 50–115)] compared with controls [126 μg/L (IQR: 105–134)] (p=0.001), indicating mild iodine deficiency in the MFA group. No cases of overt hypothyroidism were detected. Conclusions: Children with multiple food allergies receiving elimination diets are at increased risk of mild iodine deficiency, even in iodine-sufficient regions, although overt thyroid dysfunction may not yet be evident. These findings highlight the importance of routine monitoring of iodine status and early nutritional interventions in this vulnerable population.
- 24 June 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (9) , 883-890
Iodine status and thyroid function in children with multiple food allergy: a prospective cross-sectional study
Objectives: Children with multiple food allergies (MFA) often follow elimination diets that restrict major dietary sources of iodine, thereby increasing the risk of iodine deficiency. This study aimed to evaluate urinary iodine concentration (UIC) and thyroid function parameters in children with MFA and to compare these findings with those of age- and sex-matched healthy controls. Methods: In this prospective cross-sectional study, 47 children aged 0–13 years with IgE-mediated MFA on elimination diets were compared with 52 age- and sex-matched healthy controls between October 2022 and March 2024. Serum thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4) were measured using electrochemiluminescence immunoassay, and UIC was determined by inductively coupled plasma mass spectrometry (ICP-MS). Anthropometric parameters were also assessed. Results: Serum TSH, fT3, and fT4 levels did not differ significantly between the MFA and control groups (p>0.05). However, median UIC was significantly lower in the MFA group [86 μg/L (IQR: 50–115)] compared with controls [126 μg/L (IQR: 105–134)] (p=0.001), indicating mild iodine deficiency in the MFA group. No cases of overt hypothyroidism were detected. Conclusions: Children with multiple food allergies receiving elimination diets are at increased risk of mild iodine deficiency, even in iodine-sufficient regions, although overt thyroid dysfunction may not yet be evident. These findings highlight the importance of routine monitoring of iodine status and early nutritional interventions in this vulnerable population.
- 18 June 2025
- Published by Springer Nature in Indian Pediatrics
- Vol. 62 (7) , 521-524
Gynecomastia in Adolescents: Impact on Mental Health and Body Image
Objective This study aimed to explore depression, anxiety, and body image issues in adolescents with gynecomastia. Methods Forty adolescents aged 12–18 years diagnosed with gynecomastia and 40 age-matched volunteer healthy adolescent boys were enrolled. Mental health issues were assessed using Beck Anxiety Inventory (BAI), Social Appearance Anxiety Scale (SAAS), the Children’s Depression Inventory (CDI), Body Cathexis Scale (BCS), and the Brief Fear of Negative Evaluation Scale (BFNE). Results The mean (SD) BFNE [29.82 (10.08) vs. 24.62 (9.96); P = 0.023] and the SAAS [42.27 (18.15) vs. 31.32 (14.71); P = 0.004] scales were significantly higher in the patient group compared to controls. A significant negative correlation was observed between age and SAAS (r = − 0.349), and age and BFNE (r = − 0.522). A significant positive correlation was seen between SAAS and the grade of gynecomastia (r = 0.479). Conclusion Early psychological support is needed to reduce distress in adolescents with gynecomastia.
- 18 June 2025
- Published by Springer Nature in Indian Pediatrics
- Vol. 62 (7) , 521-524
Gynecomastia in Adolescents: Impact on Mental Health and Body Image
Objective This study aimed to explore depression, anxiety, and body image issues in adolescents with gynecomastia. Methods Forty adolescents aged 12–18 years diagnosed with gynecomastia and 40 age-matched volunteer healthy adolescent boys were enrolled. Mental health issues were assessed using Beck Anxiety Inventory (BAI), Social Appearance Anxiety Scale (SAAS), the Children’s Depression Inventory (CDI), Body Cathexis Scale (BCS), and the Brief Fear of Negative Evaluation Scale (BFNE). Results The mean (SD) BFNE [29.82 (10.08) vs. 24.62 (9.96); P = 0.023] and the SAAS [42.27 (18.15) vs. 31.32 (14.71); P = 0.004] scales were significantly higher in the patient group compared to controls. A significant negative correlation was observed between age and SAAS (r = − 0.349), and age and BFNE (r = − 0.522). A significant positive correlation was seen between SAAS and the grade of gynecomastia (r = 0.479). Conclusion Early psychological support is needed to reduce distress in adolescents with gynecomastia.
- 23 September 2024
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 53 (2) , 227-233
Assessing adolescent gynecomastia: The role of shear wave ultrasound elastography
Objectives: Pubertal gynecomastia (PG) is defined as benign proliferation of male breast tissue. Ultrasonography is frequently used for follow‐up of symptomatic gynecomastia. Shear wave elastography (SWE) is an auxiliary tool for the diagnosis of breast disorders. Our aim is to evaluate SWE properties of breast tissue in PG.Methods: Fifty consecutive adolescents, aged 10–18 with a diagnosis of gynecomastia were prospectively included in the study. Following clinical and laboratory evaluation, participants underwent B‐mode ultrasound and classified as nodular, dendritic, and diffuse pattern. SWE and hormonal values of all groups were recorded. Then, statistical analysis was performed.Results: Briefly, 92 breasts (43 left and 49 right; 42 bilateral and 8 unilateral) were included in the analyses. There were no significant differences in clinical parameters including age, BMI‐SDS, estradiol (E2), testosterone (T), and E2/T levels within groups (p > 0.05). Breast volume and SWE levels were significantly different in all groups (p < 0.05). SWE values were significantly lower for those of dendritic pattern than in nodular pattern (p < 0.05). ROC analysis revealed that for the best the cut‐off value of 13.7 kPa, area under the curve value was 0.922 with 84% sensitivity and 87% specificity.Conclusions: SWE values were significantly lower in patients with dendritic gynecomastia than those with nodular gynecomastia. Knowledge of the SWE values for the initial diagnosis and follow‐up values could help avoid unnecessary interventions.
- 23 September 2024
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 53 (2) , 227-233
Assessing adolescent gynecomastia: The role of shear wave ultrasound elastography
Objectives: Pubertal gynecomastia (PG) is defined as benign proliferation of male breast tissue. Ultrasonography is frequently used for follow‐up of symptomatic gynecomastia. Shear wave elastography (SWE) is an auxiliary tool for the diagnosis of breast disorders. Our aim is to evaluate SWE properties of breast tissue in PG.Methods: Fifty consecutive adolescents, aged 10–18 with a diagnosis of gynecomastia were prospectively included in the study. Following clinical and laboratory evaluation, participants underwent B‐mode ultrasound and classified as nodular, dendritic, and diffuse pattern. SWE and hormonal values of all groups were recorded. Then, statistical analysis was performed.Results: Briefly, 92 breasts (43 left and 49 right; 42 bilateral and 8 unilateral) were included in the analyses. There were no significant differences in clinical parameters including age, BMI‐SDS, estradiol (E2), testosterone (T), and E2/T levels within groups (p > 0.05). Breast volume and SWE levels were significantly different in all groups (p < 0.05). SWE values were significantly lower for those of dendritic pattern than in nodular pattern (p < 0.05). ROC analysis revealed that for the best the cut‐off value of 13.7 kPa, area under the curve value was 0.922 with 84% sensitivity and 87% specificity.Conclusions: SWE values were significantly lower in patients with dendritic gynecomastia than those with nodular gynecomastia. Knowledge of the SWE values for the initial diagnosis and follow‐up values could help avoid unnecessary interventions.
- Open Access
- 26 February 2021
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 13 (1) , 34-43
Identification of Three Novel and One Known Mutation in the WFS1 Gene in Four Unrelated Turkish Families: The Role of Homozygosity Mapping in the Early Diagnosis
Bi-allelic mutations in the wolframin gene (WFS1) cause Wolfram syndrome 1 (WS1 or DIDMOAD) characterized by non-autoimmune diabetes mellitus, optic atrophy, diabetes insipidus, sensorineural deafness, urinary tract abnormalities, and neuropsychiatric disorders. Patients presenting with an incomplete phenotype of WS1 were evaluated using homozygosity mapping and subsequent whole-exome sequencing. Four unrelated consanguineous Turkish families, including seven affected children, and their unaffected parents and siblings were evaluated. Homozygosity mapping was performed, followed by whole-exome sequencing of WFS1. Mutations were classified according to results of “in silico” analyses, protein prediction, and functional consequences. Homozygosity mapping confirmed shared homozygous regions on chromosome 4 (chr4p16.1) between the affected individuals, that was absent in their unaffected siblings. Exome sequencing identified three novel (c.1215T>A, c.554G>A, c.1525_1540dup) and one known (c.1522_1523delTA) mutations in WFS1. All mutations were predicted to cause stop codon leading to early termination of protein synthesis and complete loss-of-function. All patients were found to be homozygous for the change, with parents and other unaffected siblings being carriers. Our study expands the mutation spectrum of WSF1 mutations with three novel mutations. Homozygosity mapping may provide enrichment for molecular genetic analysis and early diagnosis of WS1 patients with incomplete phenotype, particularly in consanguineous pedigrees.
- 26 February 2021
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 13 (1) , 34-43
Open AccessIdentification of Three Novel and One Known Mutation in the WFS1 Gene in Four Unrelated Turkish Families: The Role of Homozygosity Mapping in the Early Diagnosis
Bi-allelic mutations in the wolframin gene (WFS1) cause Wolfram syndrome 1 (WS1 or DIDMOAD) characterized by non-autoimmune diabetes mellitus, optic atrophy, diabetes insipidus, sensorineural deafness, urinary tract abnormalities, and neuropsychiatric disorders. Patients presenting with an incomplete phenotype of WS1 were evaluated using homozygosity mapping and subsequent whole-exome sequencing. Four unrelated consanguineous Turkish families, including seven affected children, and their unaffected parents and siblings were evaluated. Homozygosity mapping was performed, followed by whole-exome sequencing of WFS1. Mutations were classified according to results of “in silico” analyses, protein prediction, and functional consequences. Homozygosity mapping confirmed shared homozygous regions on chromosome 4 (chr4p16.1) between the affected individuals, that was absent in their unaffected siblings. Exome sequencing identified three novel (c.1215T>A, c.554G>A, c.1525_1540dup) and one known (c.1522_1523delTA) mutations in WFS1. All mutations were predicted to cause stop codon leading to early termination of protein synthesis and complete loss-of-function. All patients were found to be homozygous for the change, with parents and other unaffected siblings being carriers. Our study expands the mutation spectrum of WSF1 mutations with three novel mutations. Homozygosity mapping may provide enrichment for molecular genetic analysis and early diagnosis of WS1 patients with incomplete phenotype, particularly in consanguineous pedigrees.
- Open Access
- 1 September 2020
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 12 (3) , 295-302
Evaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey
Objective: The aim was to determine the final adult height (FAH) achieved by recombinant human growth hormone (rhGH) treatment, the factors affecting (FAH) and the success of attaining the genetic potential. Methods: Data of 133 patients treated with rhGH therapy were reviewed retrospectively. Patients were grouped according to diagnosis, either isolated GH deficiency (IGHD) or multiple pituitary hormone deficiency (MPHD), and by sex, and pubertal status at the beginning of treatment. Results: The mean age of initiation of treatment was 12.3 +/- 2.18 years, and the mean duration of rhGH treatment was 3.65 +/- 1.5 years. The mean height standard deviation score (SDS) at diagnosis was -3.11 +/- 0.75 SD. All patients received a standardized GH dose of 0.033 mg/kg/day. Mean FAH-SDS was -1.8 +/- 0.77 and delta height-SDS (the change in height SDS between the beginning and end of treatment) was 1.28 +/- 0.94 SD. FAH-SDS was -1.79 +/- 0.86 SD in males; -1.82 +/- 0.64 in females (p =0.857); -1.94 +/- 0.71 at the beginning of treatment in pubertal patients and -1.68 +/- 0.81 in prepubertal patients (p = 0.056); -1.84 +/- 0.89 in patients with IGHD and -0.47 +/- 0.2 in patients with MPHD (p>0.05). In multiple regression analysis, First year delta height-SDS was the most predictive factor for both FAH-SDS and delta height-SDS. Conclusion: The majority of our patients achieved a final height compatible with their genetic potential as well as population standards when treated with rhGH even having started at a relatively late age. First year delta height-SDS was a predictive factor for FAH.
- 1 September 2020
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 12 (3) , 295-302
Open AccessEvaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey
Objective: The aim was to determine the final adult height (FAH) achieved by recombinant human growth hormone (rhGH) treatment, the factors affecting (FAH) and the success of attaining the genetic potential. Methods: Data of 133 patients treated with rhGH therapy were reviewed retrospectively. Patients were grouped according to diagnosis, either isolated GH deficiency (IGHD) or multiple pituitary hormone deficiency (MPHD), and by sex, and pubertal status at the beginning of treatment. Results: The mean age of initiation of treatment was 12.3 +/- 2.18 years, and the mean duration of rhGH treatment was 3.65 +/- 1.5 years. The mean height standard deviation score (SDS) at diagnosis was -3.11 +/- 0.75 SD. All patients received a standardized GH dose of 0.033 mg/kg/day. Mean FAH-SDS was -1.8 +/- 0.77 and delta height-SDS (the change in height SDS between the beginning and end of treatment) was 1.28 +/- 0.94 SD. FAH-SDS was -1.79 +/- 0.86 SD in males; -1.82 +/- 0.64 in females (p =0.857); -1.94 +/- 0.71 at the beginning of treatment in pubertal patients and -1.68 +/- 0.81 in prepubertal patients (p = 0.056); -1.84 +/- 0.89 in patients with IGHD and -0.47 +/- 0.2 in patients with MPHD (p>0.05). In multiple regression analysis, First year delta height-SDS was the most predictive factor for both FAH-SDS and delta height-SDS. Conclusion: The majority of our patients achieved a final height compatible with their genetic potential as well as population standards when treated with rhGH even having started at a relatively late age. First year delta height-SDS was a predictive factor for FAH.
- Open Access
- 27 January 2020
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 14 (1) , 72-79
Santral Tiroid Hormon Direnci Saptanan Olgularda Tiroid Hormon Reseptör Gen Analizi ve Periferik Direnç Eşliğinin Araştırılması.
Amaç: Hipofizer tiroid hormon (TH) direnci düşünülen ve klinik bulguların ayırdettirici olmadığı çocuk olgularda periferik direnç eşliğinin değerlendirilmesi ve TH β reseptörü (TRβ) mutasyon sıklığının belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Hipofizer TH direnci tanısı ile izlenen ve yeterli dozda levotiroksin (L-T4) tedavisi almalarına rağmen izlem süreçlerinde tiroid stimülan hormon (TSH) düzeyleri baskılanamayan, 20 olgu (13 kız, ort yaş 7.03±2.72 yıl,) çalışmaya alınmıştır. TH periferik etkileri, suprafizyolojik doz levotriiodotironin (L-T3) uygulaması öncesi ve sonrası serbest T3 (sT3), serbest T4 (sT4), TSH, seks hormon bağlayıcı globulin (SHBG), total kolesterol, alkalen fosfataz (ALP), osteokalsin, anjiotensin konverting enzim (ACE) düzeyleri ve kreatin fosfokinaz (CPK), M-mod ve Doppler ekokardiyografi (EKO) tetkikleri ile değerlendirilmiş ve TRβ gen analizleri yapılmıştır. Bulgular: Olguların L-T3 öncesi ve sonrası biyokimyasal ölçütleri karşılaştırıldığında SHBG, osteokalsin, ACE düzeylerinde anlamlı artış, total kolesterol ve CPK düzeylerinde ise anlamlı ölçüde azalma olduğu gözlenmiştir (pA değişimi saptanmıştır. Sonuç: Olgularımızda suprafizyolojik L-T3 konsantrasyonlarına değişik derecelerde periferik doku yanıtının gözlenmesi, yüksek T3 düzeylerine yanıtın korunduğunun göstergesidir ve en yüksek yanıtın oluştuğu SHBG ve CPK değişimleri yol gösterici olabilir. TRβ gen analizinde saptanan iki değişimin direnç patogenezinde rolü olmadığı düşünülmüştür. Yeterli tedavi kriterleri taşımalarına rağmen TSH düzeyleri ısrarlı yüksek seyreden doğumsal hipotiroid olgularda genetik bir anomali eşliğinden çok, hipotalamus-hipofiz-tiroid ekseninin intrauterin dönem olgunlaşma sürecindeki fonksiyonel bir hatanın sorumlu olduğu düşünülebilir.
- 27 January 2020
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 14 (1) , 72-79
Open AccessSantral Tiroid Hormon Direnci Saptanan Olgularda Tiroid Hormon Reseptör Gen Analizi ve Periferik Direnç Eşliğinin Araştırılması.
Amaç: Hipofizer tiroid hormon (TH) direnci düşünülen ve klinik bulguların ayırdettirici olmadığı çocuk olgularda periferik direnç eşliğinin değerlendirilmesi ve TH β reseptörü (TRβ) mutasyon sıklığının belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Hipofizer TH direnci tanısı ile izlenen ve yeterli dozda levotiroksin (L-T4) tedavisi almalarına rağmen izlem süreçlerinde tiroid stimülan hormon (TSH) düzeyleri baskılanamayan, 20 olgu (13 kız, ort yaş 7.03±2.72 yıl,) çalışmaya alınmıştır. TH periferik etkileri, suprafizyolojik doz levotriiodotironin (L-T3) uygulaması öncesi ve sonrası serbest T3 (sT3), serbest T4 (sT4), TSH, seks hormon bağlayıcı globulin (SHBG), total kolesterol, alkalen fosfataz (ALP), osteokalsin, anjiotensin konverting enzim (ACE) düzeyleri ve kreatin fosfokinaz (CPK), M-mod ve Doppler ekokardiyografi (EKO) tetkikleri ile değerlendirilmiş ve TRβ gen analizleri yapılmıştır. Bulgular: Olguların L-T3 öncesi ve sonrası biyokimyasal ölçütleri karşılaştırıldığında SHBG, osteokalsin, ACE düzeylerinde anlamlı artış, total kolesterol ve CPK düzeylerinde ise anlamlı ölçüde azalma olduğu gözlenmiştir (pA değişimi saptanmıştır. Sonuç: Olgularımızda suprafizyolojik L-T3 konsantrasyonlarına değişik derecelerde periferik doku yanıtının gözlenmesi, yüksek T3 düzeylerine yanıtın korunduğunun göstergesidir ve en yüksek yanıtın oluştuğu SHBG ve CPK değişimleri yol gösterici olabilir. TRβ gen analizinde saptanan iki değişimin direnç patogenezinde rolü olmadığı düşünülmüştür. Yeterli tedavi kriterleri taşımalarına rağmen TSH düzeyleri ısrarlı yüksek seyreden doğumsal hipotiroid olgularda genetik bir anomali eşliğinden çok, hipotalamus-hipofiz-tiroid ekseninin intrauterin dönem olgunlaşma sürecindeki fonksiyonel bir hatanın sorumlu olduğu düşünülebilir.
- Open Access
- 18 May 2018
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 10 (2) , 131-138
Restless Legs Syndrome and Poor Sleep Quality in Obese Children and Adolescents
Adult epidemiological studies suggest that the rate of Restless Legs syndrome (RLS) in the general population may range from 5% to 15%. The aim of this study was to investigate the frequency of RLS in a community sample of obese adolescents aged 10-16 years and to assess the association with sleep quality and health-related glucose metabolism markers. The study group comprised 144 obese and overweight children aged 10-16 yearsand the control group consisted of 66 age-matched healthy children. The RLS Questionnaire devised by the International RLS Study and the Pittsburgh Sleep Quality Index (PSQI), where a score >5 indicates poor sleep quality, was used to assess sleep quality. Mean body mass index (BMI) of the overweight/obese and control groups were 30.5±0.5 and 18.7±0.2, respectively. The frequency of RLS was higher in the obese group (21.7%) than the overweight (3.4%) and control (1.5%) (p<0.001) groups. The frequency of a poor PSQI score was significantly higher (p<0.001) in the obese group (37.3%) than the control group (24.2%). The obese with RLS group also had poorer sleep quality scores than the non-RLS obese group. Many symptoms of sleep disruption were more common in obese patients with RLS and RLS was independently correlated with a high PSQI score [odds ratio (OR): 2.25, confidence interval (Cl): 0.96-5.28, p<0.001)] and an increased BMI z-score (OR: 8.87, Cl: 2.04-38.61, p<0.001). RLS is common in obese children and may be associated with altered sleep quality. Obese children with RLS need to be assessed since they may need support to improve their sleep quality.
- 18 May 2018
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 10 (2) , 131-138
Open AccessRestless Legs Syndrome and Poor Sleep Quality in Obese Children and Adolescents
Adult epidemiological studies suggest that the rate of Restless Legs syndrome (RLS) in the general population may range from 5% to 15%. The aim of this study was to investigate the frequency of RLS in a community sample of obese adolescents aged 10-16 years and to assess the association with sleep quality and health-related glucose metabolism markers. The study group comprised 144 obese and overweight children aged 10-16 yearsand the control group consisted of 66 age-matched healthy children. The RLS Questionnaire devised by the International RLS Study and the Pittsburgh Sleep Quality Index (PSQI), where a score >5 indicates poor sleep quality, was used to assess sleep quality. Mean body mass index (BMI) of the overweight/obese and control groups were 30.5±0.5 and 18.7±0.2, respectively. The frequency of RLS was higher in the obese group (21.7%) than the overweight (3.4%) and control (1.5%) (p<0.001) groups. The frequency of a poor PSQI score was significantly higher (p<0.001) in the obese group (37.3%) than the control group (24.2%). The obese with RLS group also had poorer sleep quality scores than the non-RLS obese group. Many symptoms of sleep disruption were more common in obese patients with RLS and RLS was independently correlated with a high PSQI score [odds ratio (OR): 2.25, confidence interval (Cl): 0.96-5.28, p<0.001)] and an increased BMI z-score (OR: 8.87, Cl: 2.04-38.61, p<0.001). RLS is common in obese children and may be associated with altered sleep quality. Obese children with RLS need to be assessed since they may need support to improve their sleep quality.